FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has dosed the first patient in a Phase 1/2a trial of its head and neck cancer vaccine BVAC-E6E7 with in-house drug product.

  • Dosed the first BVAC-E6E7 Phase 1/2a patient at Seoul National University Hospital. Source

Roles often seen at this stageClinical & PV · Manufacturing & MSAT · Research & development

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Cellid

A biotech company developing therapeutic cancer vaccines and preventive vaccines, producing clinical drug product at its own GMP facility.

BVAC-E6E7

Phase 1

A therapeutic vaccine for HPV16- or HPV18-positive head and neck squamous cell carcinoma, in a Phase 1/2a trial at Seoul National University Hospital and Severance, supported by the Korea Drug Development Fund.

BVAC-C

Stage unconfirmed

A therapeutic vaccine candidate for cervical cancer.

Completion reported

Dosed the first patient in the BVAC-E6E7 Phase 1/2a trial with drug product made at its own GMP facility.

Official role guide

Cellid careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 셀리드, BVAC-E6E7 임상 1/2a상 첫 환자 투여 ↗뉴스핌 · Published 2026-03-05 · Sources checked 2026-11-18 · Original unavailable
  2. 2026년도 제1차 국가신약개발사업 신규지원 대상과제 선정 공고 ↗국가신약개발사업단 · Published 2026-04-30 · Sources checked 2026-11-18 · Original unavailable